Crystal structure of human angiogenin with an engineered loop exhibits conformational flexibility at the functional regions of the molecule

FEBS Open Bio

Volumn 3, Issue , 2013, Pages 65-70

  Thiyagarajan, Nethaji ^a   Acharya, K Ravi ^a  

^a University of Bath   (United Kingdom)

Author keywords

Angiogenin; Conformational flexibility; Crystal structure; Eosinophil derived neurotoxin; Protein engineering; Ribonuclease A

Indexed keywords

ANGIOGENIN; NEUROTOXIN;

ARTICLE; BINDING SITE; CARBOXY TERMINAL SEQUENCE; CLONING; CONFORMATIONAL FLEXIBILITY; CRYSTAL STRUCTURE; ENZYME ASSAY; EOSINOPHIL; MASS SPECTROMETRY; PRIORITY JOURNAL; PROTEIN CONFORMATION; PROTEIN ENGINEERING; PROTEIN EXPRESSION; PROTEIN PURIFICATION; PROTEIN STRUCTURE; X RAY CRYSTALLOGRAPHY;

EID: 84872408690     PISSN: 22115463     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.fob.2012.12.003     Document Type: Article

References (67)

1. Fett J.W., Strydom D.J., Lobb R.R., Alderman E.M., Bethune J.L., Riordan J.F., et al. Isolation and characterization of angiogenin, an angiogenic protein from human carcinoma-cells. Biochemistry 1985, 24:5480-5486.
2. Strydom D.J., Fett J.W., Lobb R.R., Alderman E.M., Bethune J.L., Riordan J.F., et al. Amino acid sequence of human tumor derived angiogenin. Biochemistry 1985, 24:5486-5494.
3. Harper J.W., Vallee B.L. A covalent angiogenin/ribonuclease hybrid with a fourth disulfide bind generated by regional mutagenesis. Biochemistry 1989, 28:1875-1884.
4. Shapiro R., Riordan J.F., Vallee B.L. Characteristic ribonucleolytic activity of human angiogenin. Biochemistry 1986, 25:3527-3532.
5. Shapiro R., Vallee B.L. Site-directed mutagenesis of histidine-13 and histidine-114 of human angiogenin alanine derivatives inhibit angiogenin induced angiogenesis. Biochemistry 1989, 28:7401-7408.
6. Li S., Hu G.F. Emerging role of angiogenin in stress response and cell survival under adverse conditions. J. Cell Physiol. 2012, 227:2822-2826.
7. Ivanov P., Emara M.M., Villen J., Gygi S.P., Anderson P. Angiogenin-induced tRNA fragments inhibit translation initiation. Mol. Cell 2011, 43:613-623.
8. Emara M.M., Ivanov P., Hickman T., Dawra N., Tisdale S., Kedersha N., et al. Angiogenin-induced tRNA-derived stress-induced RNAs promote stress-induced stress granule assembly. J. Biol. Chem. 2010, 285:10959-10968.
9. Yamasaki S., Ivanov P., Hu G.F., Anderson P. Angiogenin cleaves tRNA and promotes stress-induced translational repression. J. Cell Biol. 2009, 185:35-42.
10. Fu H., Feng J., Liu Q., Sun F., Tie Y., Zhu J., et al. Stress induces tRNA cleavage by angiogenin in mammalian cells. FEBS Lett. 2009, 583:437-442.
11. Acharya K.R., Shapiro R., Allen S.C., Riordan J.F., Vallee B.L. Crystal structure of human angiogenin reveals the structural basis for its functional divergence from ribonuclease. Proc. Natl. Acad. Sci. USA 1994, 91:2915-2919.
12. Hallahan T.W., Shapiro R., Vallee B.L. Dual site model for the organogenic activity of angiogenin. Proc. Natl. Acad. Sci. USA 1991, 88:2222-2226.
13. Moroianu J., Riordan J.F. Nuclear translocation of angiogenin in proliferating endothelial cells is essential to its angiogenic activity. Proc. Natl. Acad. Sci. USA 1994, 91:1677-1681.
14. Moroianu J., Riordan J.F. Identification of the nucleolar targeting signal of human angiogenin. Biochem. Biophys. Res. Commun. 1994, 203:1765-1772.
15. Greenway M.J., Andersen P.M., Russ C., Ennis S., Cashman S., Donaghy C., et al. Loss-of-function ANG mutations segregate with familial and 'sporadic' amyotrophic lateral sclerosis. Nat. Genet. 2006, 38:411-413.
16. Rayaprolu S., Soto-Ortolaza A., Rademakers R., Uitti R.J., Wszolek Z.K., Ross O.A. Angiogenin variation and Parkinson disease. Ann. Neurol. 2012, 71:725-727.
17. van Es M.A., Schelhaas H.J., van Vught P.W., Ticozzi N., Andersen P.M., Groen E.J., et al. Angiogenin variants in Parkinson disease and amyotrophic lateral sclerosis. Ann. Neurol. 2011, 70:964-973.
18. Subramanian V., Crabtree B., Acharya K.R. Human angiogenin is a neuroprotective factor and amyotrophic lateral sclerosis associated angiogenin variants affect neurite extension/pathfinding and survival of motor neurons. Hum. Mol. Genet. 2008, 17:130-149.
19. Kieran D., Sebastia J., Greenway M.J., King M.A., Connaughton D., Concannon C.G., et al. Control of motoneuron survival by angiogenin. J. Neurosci. 2008, 28:14056-14061.
20. Subramanian V., Feng Y. A new role for angiogenin in neurite growth and pathfinding-implications for amyotrophic lateral sclerosis. Hum. Mol. Genet. 2007, 16:1445-1453.
21. Thiyagarajan N., Ferguson R., Subramanian V., Acharya K.R. Structural and molecular insights into the mechanism of action of human angiogenin-ALS variants in neurons. Nat. Commun. 2012, 3:1121.
22. Li S., Yu W., Kishikawa H., Hu G.F. Angiogenin prevents serum withdrawal-induced apoptosis of P19 embryonal carcinoma cells. FEBS J. 2010, 277:3575-3587.
23. Kishimoto K., Liu S., Tsuji T., Olson K.A., Hu G.F. Endogenous angiogenin in endothelial cells is a general requirement for cell proliferation and angiogenesis. Oncogene 2005, 24:445-456.
24. Hirukawa S., Olson K.A., Tsuji T., Hu G.F. Neamine inhibits xenografic human tumor growth and angiogenesis in athymic mice. Clin. Cancer Res. 2005, 11:8745-8752.
25. Ibaragi S., Yoshioka N., Kishikawa H., Hu J.K., Sadow P.M., Li M., et al. Angiogenin-stimulated rRNA transcription is essential for initiation and survival of AKT-induced prostate intraepithelial neoplasia. Mol. Cancer Res. 2009, 7:415-424.
26. Olson K.A., Byers H.R., Key M.E., Fett J.W. Prevention of human prostate tumor metastasis in athymic mice by antisense targeting of human angiogenin. Clin. Cancer Res. 2001, 7:3598-3605.
27. Olson K.A., Byers H.R., Key M.E., Fett J.W. Inhibition of prostate carcinoma establishment and metastatic growth in mice by an antiangiogenin monoclonal antibody. Int. J. Cancer 2002, 98:923-929.
28. Olson K.A., Fett J.W., French T.C., Key M.E., Vallee B.L. Angiogenin antagonists prevent tumor growth in vivo. Proc. Natl. Acad. Sci. USA 1995, 92:442-446.
29. Kao R.Y., Jenkins J.L., Olson K.A., Key M.E., Fett J.W., Shapiro R. A small-molecule inhibitor of the ribonucleolytic activity of human angiogenin that possesses antitumor activity. Proc. Natl. Acad. Sci. USA 2002, 99:10066-10071.
30. Ibaragi S., Yoshioka N., Li S., Hu M.G., Hirukawa S., Sadow P.M., et al. Neamine inhibits prostate cancer growth by suppressing angiogenin-mediated rRNA transcription. Clin. Cancer Res. 2009, 15:1981-1988.
31. Yoshioka N., Wang L., Kishimoto K., Tsuji T., Hu G.F. A therapeutic target for prostate cancer based on angiogenin-stimulated angiogenesis and cancer cell proliferation. Proc. Natl. Acad. Sci. USA 2006, 103:14519-14524.
32. Harper J.W., Vallee B.L. Mutagenesis of aspartic acid-116 enhances the ribonucleolytic activity and angiogenic potency of angiogenin. Proc. Natl. Acad. Sci. USA 1988, 85:7139-7143.
33. Crabtree B., Thiyagarajan N., Prior S.H., Wilson P., Iyer S., Ferns T., et al. Characterization of human angiogenin variants implicated in amyotrophic lateral sclerosis. Biochemistry 2007, 46:11810-11818.
34. Holloway D.E., Chavali G.B., Hares M.C., Subramanian V., Acharya K.R. Structure of murine angiogenin: features of the substrate- and cell-binding regions and prospects for inhibitor-binding studies. Acta Crystallogr. D 2005, 61:1568-1578.
35. Leonidas D.D., Shapiro R., Subbarao G.V., Russo A., Acharya K.R. Crystallographic studies on the role of the C-terminal segment of human angiogenin in defining enzymatic potency. Biochemistry 2002, 41:2552-2562.
36. Leonidas D.D., Shapiro R., Allen S.C., Subbarao G.V., Veluraja K., Acharya K.R. Refined crystal structures of native human angiogenin and two active site variants: implications for the unique functional properties of an enzyme involved in neovascularisation during tumour growth. J. Mol. Biol. 1999, 285:1209-1233.
37. Acharya K.R., Shapiro R., Riordan J.F., Vallee B.L. Crystal structure of bovine angiogenin at 1.5 Å resolution. Proc. Natl. Acad. Sci. USA 1995, 92:2949-2953.
38. Russo N., Shapiro R., Acharya K.R., Riordan J.F., Vallee B.L. Role of glutamine-117 in the ribonucleolytic activity of human angiogenin. Proc. Natl. Acad. Sci. USA 1994, 91:2920-2924.
39. Papageorgiou A.C., Shapiro R., Acharya K.R. Molecular recognition of human angiogenin by placental ribonuclease inhibitor - an X-ray crystallographic study at 2.0 Å resolution. EMBO J. 1997, 16:5162-5177.
40. Chavali G.B., Papageorgiou A.C., Olson K.A., Fett J.W., Hu G., Shapiro R., et al. The crystal structure of human angiogenin in complex with an antitumor neutralizing antibody. Structure 2003, 11:875-885.
41. Iyer S., Holloway D.E., Kumar K., Shapiro R., Acharya K.R. Molecular recognition of human eosinophil-derived neurotoxin (RNase 2) by placental ribonuclease inhibitor. J. Mol. Biol. 2005, 347:637-655.
42. Domachowske J.B., Dyer K.D., Bonville C.A., Rosenberg H.F. Recombinant human eosinophil-derived neurotoxin/RNase 2 functions as an effective antiviral agent against respiratory syncytial virus. J. Infect. Dis. 1998, 177:1458-1464.
43. Domachowske J.B., Rosenberg H.F. Eosinophils inhibit retroviral transduction of human target cells by a ribonuclease-dependent mechanism. J. Leukoc. Biol. 1997, 62:363-368.
44. Gleich G.J., Jacoby D.B., Fryer A.D. Eosinophil-associated inflammation in bronchial asthma: a connection to the nervous system. Int. Arch. Allergy Immunol. 1995, 107:205-207.
45. Hamann K.J., Barker R.L., Loegering D.A., Gleich G.J. Comparative toxicity of purified human eosinophil granule proteins for newborn larvae of Trichinella spiralis. J. Parasitol. 1987, 73:523-529.
46. Sorrentino S., Glitz D.G., Hamann K.J., Loegering D.A., Checkel J.L., Gleich G.J. Eosinophil-derived neurotoxin and human liver ribonuclease. Identity of structure and linkage of neurotoxicity to nuclease activity. J. Biol. Chem. 1992, 267:14859-14865.
47. Durack D.T., Ackerman S.J., Loegering D.A., Gleich G.J. Purification of human eosinophil-derived neurotoxin. Proc. Natl. Acad. Sci. USA 1981, 78:5165-5169.
48. Raines R.T., Toscano M.P., Nierengarten D.M., Ha J.H., Auerbach R. Replacing a surface loop endows ribonuclease A with angiogenic activity. J. Biol. Chem. 1995, 270:17180-17184.
49. Hedstrom L., Szilagyi L., Rutter W.J. Converting trypsin to chymotrypsin: the role of surface loops. Science 1992, 255:1249-1253.
50. Allemann R.K., Presnell S.R., Benner S.A. A hybrid of bovine pancreatic ribonuclease and human angiogenin: an external loop as a module controlling substrate specificity?. Protein Eng. 1991, 4:831-835.
51. Hynes T.R., Kautz R.A., Goodman M.A., Gill J.F., Fox R.O. Transfer of a beta-turn structure to a new protein context. Nature 1989, 339:73-76.
52. Harper J.W., Vallee B.L. A covalent angiogenin/ribonuclease hybrid with a fourth disulfide bond generated by regional mutagenesis. Biochemistry 1989, 28:1875-1884.
53. Holloway D.E., Hares M.C., Shapiro R., Subramanian V., Acharya K.R. High-level expression of three members of the murine angiogenin family in Escherichia coli and purification of the recombinant proteins. Protein Expression Purif. 2001, 22:307-317.
54. Otwinowski Z., Minor W. Processing of X-ray diffraction data collected in oscillation mode. Methods Enzymol. 1997, 276:307-326.
55. Vagin A., Teplyakov A. MOLREP: an automated program for molecular replacement. J. Appl. Crystallogr. 1997, 30:1022-1025.
56. McCoy A.J., Grosse-Kunstleve R.W., Adams P.D., Winn M.D., Storoni L.C., Read R.J. Phaser crystallographic software. J. Appl. Crystallogr. 2007, 40:658-674.
57. Emsley P., Cowtan K. Coot: model-building tools for molecular graphics. Acta Crystallogr. D 2004, 60:2126-2132.
58. Adams P.D., Afonine P.V., Bunkóczi G., Chen V.B., Davis I.W., Echols N., et al. PHENIX: a comprehensive Python-based system for macromolecular structure solution. Acta Crystallogr. D 2010, 66:213-221.
59. Chen V.B., Arendall 3rd W.B., Headd J.J., Keedy D.A., Immormino R.M., Kapral G.J., et al. MolProbity: all-atom structure validation for macromolecular crystallography. Acta Crystallogr. D 2010, 66:12-21.
60. Davis I.W., Leaver-Fay A., Chen V.B., Block J.N., Kapral G.J., Wang X., et al. MolProbity: all-atom contacts and structure validation for proteins and nucleic acids. Nucleic Acids Res. 2007, 35:W375-W383.
61. Boerema D.J., Tereshko V.A., Kent S.B. Total synthesis by modern chemical ligation methods and high resolution (1.1 Å) X-ray structure of ribonuclease A. Biopolymers 2008, 90:278-286.
62. Swaminathan G.J., Holloway D.E., Veluraja K., Acharya K.R. Atomic resolution (0.98 Å) structure of eosinophil-derived neurotoxin. Biochemistry 2002, 41:3341-3352.
63. Lee F.S., Vallee B.L. Binding of placental ribonuclease inhibitor to the active site of angiogenin. Biochemistry 1989, 28:3556-3561.
64. Lee F.S., Shapiro R., Vallee B.L. Tight-binding inhibition of angiogenin and ribonuclease A by placental ribonuclease inhibitor. Biochemistry 1989, 28:225-230.
65. Shapiro R., Vallee B.L. Identification of functional arginines in human angiogenin by site-directed mutagenesis. Biochemistry 1992, 31:12477-12485.
66. Hallahan T.W., Shapiro R., Strydom D.J., Vallee B.L. Importance of asparagine-61 and asparagine-109 to the angiogenic activity of human angiogenin. Biochemistry 1992, 31:8022-8029.
67. Lequin O., Thuring H., Robin M., Lallemand J.Y. Three-dimensional solution structure of human angiogenin determined by 1H,15N-NMR spectroscopy-characterization of histidine protonation states and pKa values. Eur. J. Biochem. 1997, 250:712-726.